IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

Javier Cortés, Fabrice André, Anthony Gonçalves, Sherko Kümmel, Miguel Martín, Peter Schmid, Florian Schuetz, Sandra M. Swain, Valerie Easton, Erika Pollex, Regula Deurloo, Rebecca Dent

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    55 Citations (Scopus)

    Résumé

    The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC significantly improved progression-free survival and showed a clinically meaningful effect on overall survival in patients with PD-L1-positive tumors. The placebo-controlled randomized Phase III IMpassion132 (NCT03371017) trial is evaluating atezolizumab with first-line chemotherapy (capecitabine [mandatory in platinum-pretreated patients] or gemcitabine/carboplatin) for inoperable locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy. Stratification factors are: visceral metastases, tumor immune cell PD-L1 status and selected chemotherapy. Patients are randomized to atezolizumab 1200 mg or placebo every 3 weeks with the chosen chemotherapy, continued until progression, unacceptable toxicity or withdrawal. The primary end point is overall survival.

    langue originaleAnglais
    Pages (de - à)1951-1961
    Nombre de pages11
    journalFuture Oncology
    Volume15
    Numéro de publication17
    Les DOIs
    étatPublié - 1 juin 2019

    Contient cette citation